Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
Launched by HEART RHYTHM CLINICAL AND RESEARCH SOLUTIONS, LLC · Sep 10, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a treatment called catheter ablation works for people with two types of heart rhythm problems known as Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PsAF). Catheter ablation is a procedure that uses heat to destroy small areas of heart tissue that may be causing these irregular heartbeats. The goal of the study is to gather real-world information on how effective and safe this treatment is for patients, as well as how smoothly the procedure goes.
To participate in this trial, you must be at least 18 years old and have been diagnosed with either symptomatic Paroxysmal or Persistent Atrial Fibrillation, meaning your heart rhythm problems are causing noticeable symptoms. You should be a candidate for the ablation procedure and be willing to attend follow-up evaluations. However, if you have a more severe form of Atrial Fibrillation that has lasted over a year, or if you're currently in another clinical trial, you might not be eligible. Participants can expect to contribute valuable information that could help improve treatment options for others with similar heart conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
- • 18 years of age or older
- • De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry
- • Able and willing to participate in baseline and follow up evaluations for the full length of the registry
- • Willing and able to provide informed consent, if applicable
- Exclusion Criteria:
- • Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
- • Long-standing persistent AF (AF greater than one year's duration)
- • Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry
- • In the opinion of the investigator, any known contraindication to an ablation procedure
About Heart Rhythm Clinical And Research Solutions, Llc
Heart Rhythm Clinical and Research Solutions, LLC is a dedicated organization specializing in the advancement of cardiovascular health through innovative clinical trial management and research initiatives. With a focus on heart rhythm disorders, the company collaborates with healthcare professionals, institutions, and industry partners to design and implement rigorous clinical studies aimed at improving patient outcomes. Leveraging a team of experienced researchers and clinicians, Heart Rhythm Clinical and Research Solutions is committed to fostering scientific discovery and translating findings into effective therapeutic strategies, ultimately enhancing the quality of care for individuals with heart rhythm abnormalities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Iowa City, Iowa, United States
Portland, Maine, United States
Sarasota, Florida, United States
Royal Oak, Michigan, United States
Columbia, Missouri, United States
Birmingham, Alabama, United States
Savannah, Georgia, United States
Winston Salem, North Carolina, United States
Cincinnati, Ohio, United States
Asheville, North Carolina, United States
Haddon Heights, New Jersey, United States
Ypsilanti, Michigan, United States
Aurora, Colorado, United States
Oklahoma City, Oklahoma, United States
Los Angeles, California, United States
Lancaster, Pennsylvania, United States
Evanston, Illinois, United States
Salt Lake City, Utah, United States
Santa Barbara, California, United States
Rock Hill, South Carolina, United States
Greenville, South Carolina, United States
Naples, Florida, United States
Littleton, Colorado, United States
Atlanta, Georgia, United States
Springfield, Missouri, United States
Winchester, Virginia, United States
York, Pennsylvania, United States
Tacoma, Washington, United States
Lansing, Michigan, United States
Birmingham, Alabama, United States
Jackson, Mississippi, United States
Newmarket, Ontario, Canada
Dallas, Texas, United States
Lynchburg, Virginia, United States
Jonesboro, Arkansas, United States
Pittsburgh, Pennsylvania, United States
Jacksonville, Florida, United States
Columbus, Ohio, United States
Pensacola, Florida, United States
Boston, Massachusetts, United States
Mobile, Alabama, United States
Walnut Creek, California, United States
Honolulu, Hawaii, United States
Indianapolis, Indiana, United States
Louisville, Kentucky, United States
Albuquerque, New Mexico, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Chandler, Arizona, United States
Detroit, Michigan, United States
Janesville, Wisconsin, United States
Ventura, California, United States
Rock Hill, South Carolina, United States
Dallas, Texas, United States
Springfield, Illinois, United States
Lanham, Maryland, United States
Poughkeepsie, New York, United States
Miami, Florida, United States
Lansing, Michigan, United States
Midlothian, Virginia, United States
Saint Matthews, Kentucky, United States
Golden, Colorado, United States
Winter Haven, Florida, United States
Richmond, Virginia, United States
Edmonton, Alberta, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials